Recruiting

NCT Number: NCT06362304

99mTc-CNDG SPECT/CT in Brain Tumors

The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:

1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?

Participants will:

Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Intracranial Tumor Brain Diseases Brain Neoplasms Central Nervous System Diseases Central Nervous System Neoplasms Neoplasms Neoplasms by Site Nervous System Diseases Nervous System Neoplasms

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

Location status: Recruiting

Location contact

Zhaohui Zhu

CONTACT

[email protected]

010-69154241

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with clinical diagnosis of brain tumor;
Be at least 18 years old;
The final pathological results could be obtained by surgery or biopsy;
Informed consent and the ability to be followed up;
Those who did not meet the exclusion criteria.

Exclusion criteria

Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before 99mTc-CNDG injection;
Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
Severe hypersensitivity or hypersensitivity to radiocontrast agents;
Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
Patients receiving radiotherapy and chemotherapy;
Being pregnant or breastfeeding.

Treatment and study plan

99mTc-CNDG SPECT/CT

Diagnostic Test

FDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.

Primary outcomes

SUVmax

Time frame: 1month
- Diagnostic consistency evaluation of 99mTc-CNDG and 18F-FDG; 2.Correlation of SUV value of 99mTc-CNDGwith tumor type

Study contacts

Contact information is provided by the study sponsor or research team.

Zhaohui Zhu

CONTACT

[email protected]

01069154241

Sponsors and collaborators

Lead sponsor

Peking Union Medical College Hospital

Other

Registry information

Official study title

Application of 99mTc-CNDG SPECT/CT Imaging in the Diagnosis of Brain Tumors

Important dates

Study start: 2024
Primary completion: 2025
Study completion: 2025
First posted: Apr 12, 2024
Registry last updated: Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting